#Biosplusevents Join us on 14.09 for the Run for Hope 2024, held for the first time in Bellinzona! Starting at Castelgrande and passing through Bios+, this meaningful event supports important research projects in Ticino, including some at IOR and IRB. ➡ More info: https://shorturl.at/I2PZo
Institute of Oncology Research (IOR)
Forschungsdienstleistungen
Bellinzona, Canton Ticino 2.121 Follower:innen
Fighting cancer through research in cancer biology, immunology and genomics
Info
The Institute of Oncology Research (IOR), established in 2003 in Bellinzona, Switzerland, hosts researchers from all over the world performing basic and translational research in oncology with special focus on: - cancer biology - genomics - molecular oncology - experimental therapeutics. The IOR is located in a brand-new high-tech research building that hosts more than 20 different research groups, with state-of-the-art labs and facilities. Together with the Institute for Research in Biomedicine (IRB), the IOR is member of the Bellinzona Institutes of Science (Bios⁺), a recently established non-profit association aiming to promote, support and coordinate scientific research and teaching activities of its members.
- Website
-
http://www.ior.usi.ch
Externer Link zu Institute of Oncology Research (IOR)
- Branche
- Forschungsdienstleistungen
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Bellinzona, Canton Ticino
- Art
- Nonprofit
- Gegründet
- 2003
Orte
-
Primär
Wegbeschreibung
Via Francesco Chiesa 5
Bellinzona, Canton Ticino 6500, CH
Beschäftigte von Institute of Oncology Research (IOR)
Updates
-
#IORnews A new study reveals a groundbreaking compound targeting the WAS protein with anti-cancer activity in hematological cancers. ➡ Read the news : https://shorturl.at/2ROUR
-
#IORnews Researchers from the Prostate Cancer Biology Laboratory, directed by Dr. Giuseppina Carbone, have found that an enzyme involved in the cell metabolism has a critical role in the development of treatment-refractory prostate cancers. Read more: https://shorturl.at/PFQUI
-
#IORjobs Prof. Andrea Alimonti's lab is offering two 4-year postdoctoral fellowships to study the role of gut and intratumoral microbiota in cancer and treatment resistance. 👉 Discover more and apply: https://shorturl.at/Xoi5E
-
#IORnews New study led by Prof. Francesco Bertoni’s Lab, with a collaborative effort from prominent institutions, explores the potent anti-cancer activity of loncastuximab tesirine, an antibody-drug conjugate (ADC) targeting CD19-positive #lymphoma. Read the news: https://shorturl.at/3L3F6
-
#IORjobs Prof. Andrea Alimonti's lab is offering two 4-year postdoctoral fellowships to study the role of gut and intratumoral microbiota in cancer and treatment resistance. 👉 Discover more and apply: https://shorturl.at/0MSXh
-
#IORnews IOR: new anti-aging therapy identified in collaboration with the University of Padua and the Veneto Institute of Molecular Medicine (VIMM) "Preclinical studies conducted by our research team have shown that a low dose of a botanical extract of Salvia haenkei can prolong life expectancy in a healthier way," says Prof. Andrea Alimonti. ➡ Read the full news: https://shorturl.at/AZIz3 🔗 The study: https://shorturl.at/O4Ulk
-
#IORnews Macomics Ltd, a leader in macrophage drug discovery, announces that it has entered a scientific collaboration with Prof. Andrea Alimonti at IOR. 🔗 Read more: https://shorturl.at/Ddgfw
-
#IORnews 👏Congratulations to Viola Moscarda, young researcher at the IOR, for being selected as one of the winners of the 11th edition of the Fellowships sponsored by the IBSA Foundation for scientific research in the field of Healthy Aging. 🔗🗞️https://shorturl.at/1ZEoh
-
#IORnews 👏 🏆 Congratulations to Professor Andrea Alimonti, for being awarded the prestigious 2024 Cloëtta Prize! This accolade recognizes his exceptional contributions to cancer research. 🔗 Read the news: https://shorturl.at/Skxrg